Article Information
- Received June 13, 2017
- Revision received August 8, 2017
- Accepted August 14, 2017
- Published online September 4, 2017.
Author Information
- Nicholas A. Steinmetz1,2,
- Christina Buetfering3,4,
- Jerome Lecoq5,
- Christian R. Lee6,
- Andrew J. Peters2,
- Elina A. K. Jacobs1,
- Philip Coen1,
- Douglas R. Ollerenshaw5,
- Matthew T. Valley5,
- Saskia E. J. de Vries5,
- Marina Garrett5,
- Jun Zhuang5,
- Peter A. Groblewski5,
- Sahar Manavi5,
- Jesse Miles5,
- Casey White5,
- Eric Lee5,
- Fiona Griffin5,
- Joshua D. Larkin5,
- Kate Roll5,
- Sissy Cross5,
- Thuyanh V. Nguyen5,
- Rachael Larsen5,
- Julie Pendergraft5,
- Tanya Daigle5,
- Bosiljka Tasic5,
- Carol L. Thompson5,
- Jack Waters5,
- Shawn Olsen5,
- David J. Margolis6,
- Hongkui Zeng5,
- Michael Hausser3,4,
- Matteo Carandini2 and
- Kenneth D. Harris1,3
- 1UCL Institute of Neurology, University College London, London, UK
- 2UCL Institute of Ophthalmology, University College London, London, UK
- 3Department of Neuroscience, Physiology, and Pharmacology, University College London, London, UK
- 4Wolfson Institute for Biomedical Research, University College London, London, UK
- 5 Allen Institute for Brain Science, Seattle, WA
- 6Department of Cell Biology and Neuroscience, Rutgers, the State University of New Jersey, Piscataway, NJ
- Correspondence should be addressed to Nicholas A. Steinmetz. Wing 2.1, Crucifrom Building University College London London WC1E 6AE. E-mail: nick.steinmetz{at}gmail.com.
Author contributions
Author contributions: N.A.S., C.B., J.L., C.R.L., A.J.P., E.A.K.J., D.R.O., M.T.V., S.E.J.d.V., M.G., P.A.G., J.P., B.T., J.W., S.O., D.J.M., H.Z., M.H., M.C., and K.D.H. designed research; N.A.S., C.B., C.R.L., A.J.P., E.A.K.J., P.C., D.R.O., M.T.V., M.G., J.Z., S.M., J.M., C.W., E.L., F.G., J.D.L., K.R., S.C., T.V.N., R.L., J.P., and D.J.M. performed research; N.A.S., C.B., J.L., C.R.L., A.J.P., D.R.O., M.T.V., S.E.J.d.V., M.G., C.W., E.L., F.G., J.D.L., K.R., S.C., T.V.N., J.P., T.D., C.L.T., D.J.M., and K.D.H. analyzed data; N.A.S., C.B., J.L., C.R.L., A.J.P., E.A.J., D.R.O., M.V., S.E.J.d.V., M.G., B.T., C.T., J.W., D.J.M., M.C., and K.D.H. wrote the paper.
Disclosures
Authors report no conflict of interest.
EC | Horizon 2020 (EU Framework Programme for Research and Innovation); Human Frontier Science Program (HFSP); European Molecular Biology Organization (EMBO); Wellcome; Biotechnology and Biological Sciences Research Council (BBSRC); EC | European Research Council (ERC); New Jersey Commission on Brain Injury Research (NJCBIR); National Science Foundation (NSF); HHS | National Institutes of Health (NIH). N.A.S. was supported by postdoctoral fellowships from the HFSP and the Marie Curie Action of the EU. C.B. was supported by an EMBO Long-Term Fellowship and the Marie Curie Action of the EU. M.H. was supported by the Wellcome Trust, BBSRC, and ERC. D.J.M. was supported by the NJCBIR, the NSF, and NIH. M.C. holds the GlaxoSmithKline / Fight for Sight Chair in Visual Neuroscience.
Funding
EC | Horizon 2020 (EU Framework Programme for Research and Innovation)
Human Frontier Science Program (HFSP)
European Molecular Biology Organization (EMBO)
Wellcome
Biotechnology and Biological Sciences Research Council (BBSRC)
EC | European Research Council (ERC)
New Jersey Commission on Brain Injury Research (NJCBIR)
National Science Foundation (NSF)
HHS | National Institutes of Health (NIH)
Other Version
- You are viewing the most recent version of this article.
- previous version (September 04, 2017).
Article usage
In this issue
